- Conditions
- Thrombocytosis, Myeloproliferative Neoplasms
- Interventions
- Anagrelide CR
- Drug
- Lead sponsor
- Galena Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 11
- States / cities
- Burbank, California • Encinitas, California • Escondido, California + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2593–2616
of 33,600
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Primary Brain Tumors, Metastatic Malignant Neoplasm to Brain
- Interventions
- 4-Demethyl-4-cholestryloxycarbonylpenclomedine
- Drug
- Lead sponsor
- DEKK-TEC, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 3
- States / cities
- New Orleans, Louisiana • Lansing, Michigan • Houston, Texas
- Conditions
- HIV Enteropathy, Diarrhea With HIV
- Interventions
- Crofelemer
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 16 more
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- KHK4951, Aflibercept Injection
- Drug
- Lead sponsor
- Kyowa Kirin Co., Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 38
- States / cities
- Mesa, Arizona • Tucson, Arizona • Arcadia, California + 34 more
- Conditions
- Ovarian Cancer
- Interventions
- DNIB0600A, PLD
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Orange, California + 9 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Tofacitinib, TNF Inhibitor
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 105,711 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Influenza, Virus Diseases
- Interventions
- Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Depressive Disorder, Treatment-Resistant
- Interventions
- Esketamine 56 mg, Esketamine 84 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 44 more
- Conditions
- Influenza, Healthy
- Interventions
- Trivalent Influenza Vaccine, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 3
- States / cities
- Miami, Florida • Stockbridge, Georgia • Portland, Oregon
- Conditions
- Heart Failure
- Interventions
- BMS-986231 Formulation A, BMS-986231 Formulation B, BMS-986231 Formulation C, BMS-986231 Formulation D
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Cenerimod, Placebo
- Drug
- Lead sponsor
- Viatris Innovation GmbH
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 451 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • La Jolla, California • Northridge, California + 12 more
- Conditions
- Avian Influenza, Influenza Immunisation
- Interventions
- Aqueous Cream B.P., Imiquimod, Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04
- Other · Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Alzheimer's Disease
- Interventions
- Bapineuzumab (AAB-001)
- Drug
- Lead sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 29
- States / cities
- Peoria, Arizona • Sun City, Arizona • Encino, California + 26 more
- Conditions
- Allergic Rhinitis
- Interventions
- 205.5 mcg of azelastine hydrochloride, 137 mcg of azelastine hydrochloride
- Drug
- Lead sponsor
- Meda Pharmaceuticals
- Industry
- Eligibility
- 6 Months to 5 Years
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Little Rock, Alaska • Costa Mesa, California + 9 more
- Conditions
- Hodgkin Lymphoma, Non Hodgkin Lymphoma
- Interventions
- AB-205, Placebo
- Biological · Other
- Lead sponsor
- Angiocrine Bioscience
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 28
- States / cities
- Gilbert, Arizona • Duarte, California • Los Angeles, California + 22 more
- Conditions
- Alzheimer's Disease
- Interventions
- Aducanumab
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 1,696 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 104
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 82 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Certolizumab Pegol, Placebo, Methotrexate
- Biological · Other
- Lead sponsor
- UCB Pharma SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 880 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more
- Conditions
- Leukoplakia, Erythroplakia
- Interventions
- PDL-585, ScleroPLUS laser, 5-Aminolevulinic Acid (Levulan KerastickTM), Fluorescence Diagnosis Imaging
- Device · Drug · Procedure
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Safety of Neosaxitoxin in Healthy Volunteers
- Interventions
- Neosaxitoxin in saline, NeoSTX + bupivacaine 0.2%, NeoSTX + bupivacaine 0.2% + epinephrine 5mcg/ml, Saline placebo
- Drug · Other
- Lead sponsor
- Charles Berde
- Other
- Eligibility
- 18 Years to 35 Years · Male only
- Enrollment
- 105 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Autism Spectrum Disorder
- Interventions
- GWP42003-P, Placebo
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 9 more
- Conditions
- Healthy Participants
- Interventions
- CK-3828136, Placebo for CK-3828136
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Hepatitis C, HIV Infections
- Interventions
- Double dose pegylated interferon with weight based Ribavirin, standard dose pegylated interferon alfa -2a and ribavirin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cushing's Syndrome
- Interventions
- CORT125134
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 12
- States / cities
- Laguna Hills, California • Aurora, Colorado • Fort Lauderdale, Florida + 9 more
- Conditions
- Healthy
- Interventions
- TT-01025-CL
- Drug
- Lead sponsor
- LG Chem
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada